{"denoms":[{"counts":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"132"},{"groupId":"BG002","value":"267"}],"units":"Participants"}],"groups":[{"description":"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.\n\nIMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm C.\n\nPatients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nComputed Tomography: Undergo CT\n\nEchocardiography Test: Undergo ECHO\n\nIpilimumab: Given IV\n\nMultigated Acquisition Scan: Undergo MUGA scan\n\nNivolumab: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"BG000","title":"Arm A (Immunotherapy)"},{"description":"Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm D.\n\nPatients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nComputed Tomography: Undergo CT\n\nDabrafenib Mesylate: Given PO\n\nEchocardiography Test: Undergo ECHO\n\nMultigated Acquisition Scan: Undergo MUGA scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nTrametinib Dimethyl Sulfoxide: Given PO","id":"BG001","title":"Arm B (BRAF Inhibitor Therapy)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"29","upperLimit":"83","value":"59"},{"groupId":"BG001","lowerLimit":"25","upperLimit":"84","value":"60"},{"groupId":"BG002","lowerLimit":"25","upperLimit":"84","value":"59"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"98"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"169"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"255"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}],"title":"Non-White"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"All randomized patients"}